Anastasiia P Shuliak

Anastasiia P Shuliak

Auto-generated profile, based on publicly available information

Anastasiia P Shuliak

School of Medicine and Life Sciences, Far Eastern Federal University , Vladivostok 690922

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in NAR Cancer
Verified
Journal Article
Open access
NGNikolay V Goncharov
Nikolay V Goncharov
IBIvan Baklanov
Ivan Baklanov
VGValeriia S Gulaia
Valeriia S Gulaia
ASAnastasiia P Shuliak
Anastasiia P Shuliak
DLDaria Lanskikh
Daria Lanskikh
VKVadim Kumeiko
Vadim Kumeiko
Recently revised brain tumor classification suggested a glioma treatment strategy that takes into consideration molecular variants in IDH1 and TP53 marker genes. While pathogenic variants of IDH1 and TP53 can be accompanied by chromosomal instability (CIN), the impact of IDH1 and TP53 mutations on genome stability remains unstudied. Elevated CIN might provide therapeutic targets, based on synergistic effects of chemotherapy with CIN-inducing drugs. Using an assay based on human artificial chromosomes, we investigated the impact of common glioma missense mutations in IDH1 and TP53 on chromosome transmission and demonstrated that IDH1R132H and TP53R248Q variants elevate CIN. We next found enhanced CIN levels and the sensitivity of IDH1R132H/WT and TP53R248Q/R248Q genotypes, introduced into U87 MG glioma cells by CRISPR/Cas9, to different drugs, including conventional temozolomide. It was found that U87 MG cells carrying IDH1R132H/WT exhibit dramatic sensitivity to paclitaxel, which was independently confirmed on cell cultures derived from patients with naturally occurring IDH1R132H/WT. Overall, our results suggest that the development of CIN-enhancing therapy for glioma tumors with the IDH1R132H/WT genotype could be advantageous for adjuvant treatment.